Publications

Publications published since 2000 from OUS - Department of Gynaecological Oncology

449 publications found

Publications 2020

1. Lindemann K (2020)
   Systematic treatment of primary and recurrent cervical cancer
   Int. J. Gynecol. Cancer, 30 1, 15
2. Lindemann K, Martinsson L, Kaasa S, Lindquist D (2020)
   Elderly gynaecological cancer patients at risk for poor end of life care: a population-based study from the Swedish Register of Palliative Care
   Acta Oncol, 1-8 (in press)
   DOI 10.1080/0284186X.2020.1744717, PubMed 32238040
3. Paoletti X, Lewsley LA, Daniele G, Cook A, Yanaihara N, Tinker A, Kristensen G, Ottevanger PB, Aravantinos G, Miller A, Boere IA, Fruscio R, Reyners AKL, Pujade-Lauraine E, Harkin A, Pignata S, Kagimura T, Welch S, Paul J, Karamouza E, Glasspool RM, Gynecologic Cancer InterGroup (GCIG) Meta-analysis Committee (2020)
   Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis
   JAMA Netw Open, 3 (1), e1918939
   DOI 10.1001/jamanetworkopen.2019.18939, PubMed 31922558
4. Ramirez PT, Chiva L, Eriksson AGZ, Frumovitz M, Fagotti A, Gonzalez Martin A, Jhingran A, Pareja R (2020)
   COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers
   Int J Gynecol Cancer (in press)
   DOI 10.1136/ijgc-2020-001419, PubMed 32221023
5. Ramirez PT, Pareja R, Eriksson AGZ, Frumovitz M (2020)
   International Gynecologic Cancer Society 2019 meeting summary
   Int J Gynecol Cancer, 30 (2), 167-173
   DOI 10.1136/ijgc-2019-001146, PubMed 32029483
6. Vistad I, Lindemann K, Bentzen AG, Dahl AA, Steen R, Kiserud C (2020)
   Preferences for follow-up in long-term survivors after cervical cancer
   Acta Obstet Gynecol Scand (in press)
   DOI 10.1111/aogs.13855, PubMed 32232835

Publications 2019

1. Binzer-Panchal A, Hardell E, Viklund B, Ghaderi M, Bosse T, Nucci MR, Lee CH, Hollfelder N, Corcoran P, Gonzalez-Molina J, Moyano-Galceran L, Bell DA, Schoolmeester JK, Måsbäck A, Kristensen GB, Davidson B, Lehti K, Isaksson A, Carlson JW (2019)
   Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes
   Clin Cancer Res, 25 (7), 2155-2165
   DOI 10.1158/1078-0432.CCR-18-2792, PubMed 30617134
2. Eriksson AG, Fallaas Dahl G, Nesbakken AJ, Lund KV, Amant F (2019)
   Endometrial cancer during pregnancy: management strategies
   Int J Gynecol Cancer, 29 (7), 1221-1224
   DOI 10.1136/ijgc-2019-000756, PubMed 31434687
3. Fabbro M, Moore KN, Dørum A, Tinker AV, Mahner S, Bover I, Banerjee S, Tognon G, Goffin F, Shapira-Frommer R, Wenham RM, Hellman K, Provencher D, Harter P, Vázquez IP, Follana P, Pineda MJ, Mirza MR, Hazard SJ, Matulonis UA (2019)
   Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial
   Gynecol Oncol, 152 (3), 560-567
   DOI 10.1016/j.ygyno.2018.12.009, PubMed 30638768
4. Jonsson M, Fjeldbo CS, Holm R, Stokke T, Kristensen GB, Lyng H (2019)
   Mitochondrial Function of CKS2 Oncoprotein Links Oxidative Phosphorylation with Cell Division in Chemoradioresistant Cervical Cancer
   Neoplasia, 21 (4), 353-362
   DOI 10.1016/j.neo.2019.01.002, PubMed 30856376
5. Lindemann K, Zalewski K, Halaska MJ (2019)
   Summary of landmark papers published between August 2018 and May 2019
   Int. J. Gynecol. Cancer, 29 1, 1-5
6. Lund KV, Simonsen TG, Kristensen GB, Rofstad EK (2019)
   Pharmacokinetic analysis of DCE-MRI data of locally advanced cervical carcinoma with the Brix model
   Acta Oncol, 58 (6), 828-837
   DOI 10.1080/0284186X.2019.1580386, PubMed 30810443
7. Nilsen A, Jonsson M, Aarnes EK, Kristensen GB, Lyng H (2019)
   Reference MicroRNAs for RT-qPCR Assays in Cervical Cancer Patients and Their Application to Studies of HPV16 and Hypoxia Biomarkers
   Transl Oncol, 12 (3), 576-584
   DOI 10.1016/j.tranon.2018.12.010, PubMed 30660934
8. Piovano E, Ferrero A, Zola P, Marth C, Mirza MR, Lindemann K (2019)
   Clinical pathways of recovery after surgery for advanced ovarian/tubal/peritoneal cancer: an NSGO-MaNGO international survey in collaboration with AGO-a focus on surgical aspects
   Int J Gynecol Cancer, 29 (1), 181-187
   DOI 10.1136/ijgc-2018-000021, PubMed 30640702
9. Roncolato F, Lindemann K, Willson ML, Martyn J, Mileshkin L (2019)
   PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer
   Cochrane Database Syst Rev (10), CD012160
   DOI 10.1002/14651858.CD012160.pub2, PubMed 31588998
10. Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, Jayson GC, Johnson N, Swart AM, Verheijen R, McCluggage WG, Perren T, Panici PB, Kenter G, Casado A, Mendiola C, Stuart G, Reed NS, Kehoe S, EORTC MRC CHORUS Study Investigators (2019)
    Neoadjuvant Chemotherapy Versus Debulking Surgery in Advanced Tubo-Ovarian Cancers: Pooled Analysis of Individual Patient Data From the EORTC 55971 and CHORUS Trials
    Obstet. Gynecol. Surv., 74 (3), 156-158

Publications 2018

1. González Martín A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Bertrand MA, Beale P, Cervantes A, Kent E, Kaplan RS, Parmar MKB, Scotto N, Perren TJ, ICON7 investigators (2018)
   Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer
   Gynecol Oncol, 152 (1), 53-60
   DOI 10.1016/j.ygyno.2018.08.036, PubMed 30449719
2. Kleppe A, Albregtsen F, Vlatkovic L, Pradhan M, Nielsen B, Hveem TS, Askautrud HA, Kristensen GB, Nesbakken A, Trovik J, Wæhre H, Tomlinson I, Shepherd NA, Novelli M, Kerr DJ, Danielsen HE (2018)
   Chromatin organisation and cancer prognosis: a pan-cancer study
   Lancet Oncol, 19 (3), 356-369
   DOI 10.1016/S1470-2045(17)30899-9, PubMed 29402700
3. Lindemann K (2018)
   Medical treatment of primary and recurrent cervical cancer
   Int. J. Gynecol. Cancer, 28 4, 29
4. Lindemann K, Beale PJ, Rossi E, Goh JC, Vaughan MM, Tenney ME, Martyn JK, Sommeijer D, Iglesias JL, Kremmidiotis G, Simpson J, Doolin E, Lavranos TC, Leske A, Veillard AS, Espinoza D, Stockler MR, Rischin D, For ANZGOG and HCRN Collaborative Groups (2018)
   Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)
   Cancer Chemother Pharmacol, 83 (1), 97-105
   DOI 10.1007/s00280-018-3706-5, PubMed 30368585
5. Lindemann K, Gao B, Mapagu C, Fereday S, Emmanuel C, Alsop K, Traficante N, Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DDL, deFazio A (2018)
   Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance
   Gynecol Oncol, 150 (2), 239-246
   DOI 10.1016/j.ygyno.2018.05.020, PubMed 29807697
6. Lindemann K, Zalewski K, Halaska MJ, Lindquist D (2018)
   PREFACE
   Int. J. Gynecol. Cancer, 28 4, 2
7. Lønning PE, Berge EO, Bjørnslett M, Minsaas L, Chrisanthar R, Høberg-Vetti H, Dulary C, Busato F, Bjørneklett S, Eriksen C, Kopperud R, Axcrona U, Davidson B, Bjørge L, Evans G, Howell A, Salvesen HB, Janszky I, Hveem K, Romundstad PR, Vatten LJ, Tost J, Dørum A, Knappskog S (2018)
   White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk
   Ann Intern Med, 168 (5), 326-334
   DOI 10.7326/M17-0101, PubMed 29335712
8. Nielsen B, Kleppe A, Hveem TS, Pradhan M, Syvertsen RA, Nesheim JA, Kristensen GB, Trovik J, Kerr DJ, Albregtsen F, Danielsen HE (2018)
   Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological Cancers
   J Natl Cancer Inst, 110 (12), 1400-1408
   DOI 10.1093/jnci/djy063, PubMed 29684152
9. Noer MC, Leandersson P, Paulsen T, Rosthøj S, Antonsen SL, Borgfeldt C, Høgdall C (2018)
   Confounders other than comorbidity explain survival differences in Danish and Swedish ovarian cancer patients - a comparative cohort study
   Acta Oncol, 57 (8), 1100-1108
   DOI 10.1080/0284186X.2018.1440085, PubMed 29451070
10. Simonsen TG, Lund KV, Hompland T, Kristensen GB, Rofstad EK (2018)
    DCE-MRI-Derived Measures of Tumor Hypoxia and Interstitial Fluid Pressure Predict Outcomes in Cervical Carcinoma
    Int J Radiat Oncol Biol Phys, 102 (4), 1193-1201
    DOI 10.1016/j.ijrobp.2018.04.035, PubMed 29859790
11. Smogeli E, Cvancarova M, Wang Y, Davidson B, Kristensen G, Lindemann K (2018)
    Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only
    Int J Gynecol Cancer, 28 (9), 1789-1795
    DOI 10.1097/IGC.0000000000001356, PubMed 30365455
12. Solheim O, Skalleberg J, Warncke T, Ørstavik K, Tropé C, Fosså SD (2018)
    Long-term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin-based chemotherapy for malignant ovarian germ cell tumor
    Acta Obstet Gynecol Scand, 98 (2), 240-249
    DOI 10.1111/aogs.13477, PubMed 30289161
13. Szczesny W, Langseth H, Myklebust TÅ, Kaern J, Tropé C, Paulsen T (2018)
    Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based study
    Acta Obstet Gynecol Scand, 97 (8), 956-965
    DOI 10.1111/aogs.13361, PubMed 29790149

Publications 2017

1. Andersson Y, Haavardtun SI, Davidson B, Dørum A, Fleten KG, Fodstad Ø, Flatmark K (2017)
   MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
   Oncotarget, 8 (37), 61800-61809
   DOI 10.18632/oncotarget.18694, PubMed 28977905
2. Davidson B, Hellesylt E, Holth A, Danielsen HE, Skeie-Jensen T, Katz B (2017)
   Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma
   Virchows Arch, 471 (3), 355-362
   DOI 10.1007/s00428-017-2172-5, PubMed 28643014
3. Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE, Knappskog S (2017)
   MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk
   BMC Cancer, 17 (1), 97
   DOI 10.1186/s12885-017-3094-y, PubMed 28158999
4. Gutgold N, Davidson B, Catane LJ, Holth A, Hellesylt E, Tropé CG, Dørum A, Reich R (2017)
   TGFβ splicing and canonical pathway activation in high-grade serous carcinoma
   Virchows Arch, 470 (6), 665-678
   DOI 10.1007/s00428-017-2127-x, PubMed 28432432
5. Hardell E, Josefson S, Ghaderi M, Skeie-Jensen T, Westbom-Fremer S, Cheek EH, Bell D, Selling J, Schoolmeester JK, Måsbäck A, Davidson B, Carlson JW (2017)
   Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas
   Am J Surg Pathol, 41 (9), 1231-1237
   DOI 10.1097/PAS.0000000000000894, PubMed 28622181
6. Johansen N, Liavaag AH, Iversen OE, Dørum A, Braaten T, Michelsen TM (2017)
   Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy
   Acta Obstet Gynecol Scand, 96 (5), 547-555
   DOI 10.1111/aogs.13120, PubMed 28236297
7. Kildal W, Pradhan M, Cyll K, Jacobsen JE, Kristensen GB, Danielsen HE (2017)
   [Properties of cancer cell DNA affects the prognosis]
   Tidsskr Nor Laegeforen, 137 (19)
   DOI 10.4045/tidsskr.16.0966, PubMed 29043733
8. Kildal W, Pradhan M, Cyll K, Jacobsen JE, Kristensen GB, Danielsen HE (2017)
   Characteristics of tumor cell DNA affect prognosis
   Tidsskr. Nor. Laegeforen., 137 (19), 1519-1523
9. Landskron J, Kraggerud SM, Wik E, Dørum A, Bjørnslett M, Melum E, Helland Ø, Bjørge L, Lothe RA, Salvesen HB, Taskén K (2017)
   C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease
   PLoS One, 12 (7), e0182030
   DOI 10.1371/journal.pone.0182030, PubMed 28759630
10. Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P, Skeie-Jensen T, Hjerpe E, Dørum A, Gebski V, Kristensen G (2017)
    Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
    Br J Cancer, 116 (4), 455-463
    DOI 10.1038/bjc.2016.435, PubMed 28118323
11. Lindemann K, Kok PS, Stockler M, Jaaback K, Brand A (2017)
    Enhanced Recovery After Surgery for Advanced Ovarian Cancer: A Systematic Review of Interventions Trialed
    Int J Gynecol Cancer, 27 (6), 1274-1282
    DOI 10.1097/IGC.0000000000000981, PubMed 28498237
12. Lindemann K, Kok PS, Stockler M, Sykes P, Brand A (2017)
    Enhanced Recovery After Surgery for Suspected Ovarian Malignancy: A Survey of Perioperative Practice Among Gynecologic Oncologists in Australia and New Zealand to Inform a Clinical Trial
    Int J Gynecol Cancer, 27 (5), 1046-1050
    DOI 10.1097/IGC.0000000000000982, PubMed 28525497
13. Lund KV, Simonsen TG, Kristensen GB, Rofstad EK (2017)
    Pretreatment late-phase DCE-MRI predicts outcome in locally advanced cervix cancer
    Acta Oncol, 56 (5), 675-681
    DOI 10.1080/0284186X.2017.1294762, PubMed 28447564
14. Meltzer-Gunnes CJ, Småstuen MC, Kristensen GB, Tropé CG, Lie AK, Vistad I (2017)
    Vulvar carcinoma in Norway: A 50-year perspective on trends in incidence, treatment and survival
    Gynecol Oncol, 145 (3), 543-548
    DOI 10.1016/j.ygyno.2017.03.008, PubMed 28356187
15. Minig L, Heitz F, Cibula D, Bakkum-Gamez JN, Germanova A, Dowdy SC, Kalogera E, Zapardiel I, Lindemann K, Harter P, Scambia G, Petrillo M, Zorrero C, Zanagnolo V, Rebollo JMC, du Bois A, Fotopoulou C (2017)
    Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study
    Ann Surg Oncol, 24 (9), 2720-2726
    DOI 10.1245/s10434-017-5919-y, PubMed 28608122
16. Ray-Coquard I, Trama A, Seckl MJ, Fotopoulou C, Pautier P, Pignata S, Kristensen G, Mangili G, Falconer H, Massuger L, Sehouli J, Pujade-Lauraine E, Lorusso D, Amant F, Rokkones E, Vergote I, Ledermann JA, RARECARENet Working Group (2017)
    Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting
    Eur J Surg Oncol, 45 (1), 67-74
    DOI 10.1016/j.ejso.2017.09.025, PubMed 29108961
17. Skalleberg J, Solheim O, Fosså SD, Småstuen MC, Osnes T, Gundersen POM, Bunne M (2017)
    Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer
    Gynecol Oncol, 145 (1), 148-153
    DOI 10.1016/j.ygyno.2017.02.006, PubMed 28202195
18. Solheim O, Førsund M, Tropé CG, Kraggerud SM, Nesland JM, Davidson B (2017)
    Epithelial-mesenchymal transition markers in malignant ovarian germ cell tumors
    APMIS, 125 (9), 781-786
    DOI 10.1111/apm.12715, PubMed 28585395
19. Steen R, Dahl AA, Hess SL, Kiserud CE (2017)
    A study of chronic fatigue in Norwegian cervical cancer survivors
    Gynecol Oncol, 146 (3), 630-635
    DOI 10.1016/j.ygyno.2017.05.028, PubMed 28552254
20. Vistad I, Bjørge L, Solheim O, Fiane B, Sachse K, Tjugum J, Skrøppa S, Bentzen AG, Stokstad T, Iversen GA, Salvesen HB, Kristensen GB, Dørum A (2017)
    A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway
    Acta Obstet Gynecol Scand, 96 (10), 1162-1169
    DOI 10.1111/aogs.13199, PubMed 28795770
21. Wiedmann MKH, Brunborg C, Di Ieva A, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA (2017)
    Overweight, obesity and height as risk factors for meningioma, glioma, pituitary adenoma and nerve sheath tumor: a large population-based prospective cohort study
    Acta Oncol, 56 (10), 1302-1309
    DOI 10.1080/0284186X.2017.1330554, PubMed 28548875
22. Zalewski K, Lindemann K, Halaska MJ, Zapardiel I, Laky R, Chereau E, Lindquist D, Polterauer S, Sukhin V, Dursun P (2017)
    A Call for New Communication Channels for Gynecological Oncology Trainees: A Survey on Social Media Use and Educational Needs by the European Network of Young Gynecological Oncologists
    Int J Gynecol Cancer, 27 (3), 620-626
    DOI 10.1097/IGC.0000000000000917, PubMed 28187096

Publications 2016

1. Bjørge T, Skare GB, Bjørge L, Tropé A, Lönnberg S (2016)
   Adverse Pregnancy Outcomes After Treatment for Cervical Intraepithelial Neoplasia
   Obstet Gynecol, 128 (6), 1265-1273
   DOI 10.1097/AOG.0000000000001777, PubMed 27824756
2. Davidson B, Kjæreng ML, Førsund M, Danielsen HE, Kristensen GB, Abeler VM (2016)
   Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma
   Am J Clin Pathol, 145 (4), 449-58
   DOI 10.1093/ajcp/aqw030, PubMed 27149024
3. Fjeldbo CS, Julin CH, Lando M, Forsberg MF, Aarnes EK, Alsner J, Kristensen GB, Malinen E, Lyng H (2016)
   Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer
   Clin Cancer Res, 22 (16), 4067-76
   DOI 10.1158/1078-0432.CCR-15-2322, PubMed 27012812
4. Fjeldbo CS, Aarnes EK, Malinen E, Kristensen GB, Lyng H (2016)
   Identification and Validation of Reference Genes for RT-qPCR Studies of Hypoxia in Squamous Cervical Cancer Patients
   PLoS One, 11 (5), e0156259
   DOI 10.1371/journal.pone.0156259, PubMed 27244197
5. Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Dørum A, Birkeland E, Hveem K, Romundstad P, Vatten L, Lønning PE, Knappskog S (2016)
   The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer
   Tumour Biol, 37 (8), 10697-702
   DOI 10.1007/s13277-016-4940-2, PubMed 26867771
6. Gao B, Lindemann K, Anderson L, Fereday S, Hung J, Alsop K, Tothill RW, Gebski V, Kennedy C, Balleine RL, Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DD, DeFazio A (2016)
   Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome
   Gynecol Oncol, 142 (3), 458-64
   DOI 10.1016/j.ygyno.2016.06.023, PubMed 27444035
7. Grabowski JP, Harter P, Heitz F, Pujade-Lauraine E, Reuss A, Kristensen G, Ray-Coquard I, Heitz J, Traut A, Pfisterer J, du Bois A (2016)
   Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase
   Gynecol Oncol, 140 (3), 457-62
   DOI 10.1016/j.ygyno.2016.01.022, PubMed 26807488
8. Horwitz V, Davidson B, Stern D, Tropé CG, Tavor Re'em T, Reich R (2016)
   Ezrin Is Associated with Disease Progression in Ovarian Carcinoma
   PLoS One, 11 (9), e0162502
   DOI 10.1371/journal.pone.0162502, PubMed 27622508
9. Lindemann K (2016)
   Medical treatment of primary or recurrent cervical cancer
   Int. J. Gynecol. Cancer, 26 1, 42-43
10. Lindemann K, Halaska MJ, Zalewski K (2016)
    Surgical treatment of primary ovarian fallopian tube and peritoneal cancer
    Int. J. Gynecol. Cancer, 26 1, 5-8
11. Lindemann K, Kristensen G, Mirza MR, Davies L, Hilpert F, Romero I, Ayhan A, Burges A, Rubio MJ, Raspagliesi F, Huizing M, Creemers GJ, Lykka M, Lee CK, Gebski V, Pujade-Lauraine E (2016)
    Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
    Ann Oncol, 27 (8), 1505-10
    DOI 10.1093/annonc/mdw238, PubMed 27407100
12. Lindemann K, Zalewski K, Halaska MJ, LiFE Team (2016)
    Preface
    Int. J. Gynecol. Cancer, 26 1, 2
13. Lindemann K, Zalewski K, Halaska MJ, Lindquist D, The LiFE Team (2016)
    Life - Literature for ENYGO
    Int. J. Gynecol. Cancer, 26 4, 2-73
14. Lönnberg S, Andreassen T, Engesæter B, Lilleng R, Kleven C, Skare A, Johansson K, Fredheim CS, Tropé A (2016)
    Impact of scheduled appointments on cervical screening participation in Norway: a randomised intervention
    BMJ Open, 6 (11), e013728
    DOI 10.1136/bmjopen-2016-013728, PubMed 28186949
15. Makar AP, Tropé CG, Tummers P, Denys H, Vandecasteele K (2016)
    Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer
    Oncologist, 21 (6), 745-54
    DOI 10.1634/theoncologist.2015-0239, PubMed 27009938
16. Nymoen DA, Slipicevic A, Holth A, Emilsen E, Hetland Falkenthal TE, Tropé CG, Reich R, Flørenes VA, Davidson B (2016)
    MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma
    Hum Pathol, 54, 74-81
    DOI 10.1016/j.humpath.2016.03.010, PubMed 27063471
17. Sert BM, Boggess JF, Ahmad S, Jackson AL, Stavitzski NM, Dahl AA, Holloway RW (2016)
    Robot-assisted versus open radical hysterectomy: A multi-institutional experience for early-stage cervical cancer
    Eur J Surg Oncol, 42 (4), 513-22
    DOI 10.1016/j.ejso.2015.12.014, PubMed 26843445
18. Smogeli E, Davidson B, Cvancarova M, Holth A, Katz B, Risberg B, Kristensen G, Lindemann K (2016)
    L1CAM as a prognostic marker in stage I endometrial cancer: a validation study
    BMC Cancer, 16, 596
    DOI 10.1186/s12885-016-2631-4, PubMed 27488577
19. Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E, AURELIA Investigators (2016)
    Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
    Gynecol Oncol, 144 (1), 65-71
    DOI 10.1016/j.ygyno.2016.11.006, PubMed 27871723
20. Szczesny W, Vistad I, Kaern J, Nakling J, Tropé C, Paulsen T (2016)
    Impact of hospital type and treatment on long-term survival among patients with FIGO Stage IIIC epithelial ovarian cancer: follow-up through two recurrences and three treatment lines in search for predictors for survival
    Eur J Gynaecol Oncol, 37 (3), 305-11
    DOI 10.12892/ejgo3007.2016, PubMed 27352555
21. Tambe M, Pruikkonen S, Mäki-Jouppila J, Chen P, Elgaaen BV, Straume AH, Huhtinen K, Cárpen O, Lønning PE, Davidson B, Hautaniemi S, Kallio MJ (2016)
    Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel
    Oncotarget, 7 (11), 12267-85
    DOI 10.18632/oncotarget.7860, PubMed 26943585
22. Trillsch F, Mahner S, Hilpert F, Davies L, García-Martínez E, Kristensen G, Savarese A, Vuylsteke P, Los M, Zagouri F, Gladieff L, Sehouli J, Khoon Lee C, Gebski V, Pujade-Lauraine E (2016)
    Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial
    Ann Oncol, 27 (9), 1733-9
    DOI 10.1093/annonc/mdw236, PubMed 27287207
23. Zalewski K, Lindemann K, Halaska MJ (2016)
    Medical treatment of primary ovarian cancer
    Int. J. Gynecol. Cancer, 26 1, 9-11
24. Zhou C, Clamp A, Backen A, Berzuini C, Renehan A, Banks RE, Kaplan R, Scherer SJ, Kristensen GB, Pujade-Lauraine E, Dive C, Jayson GC (2016)
    Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
    Br J Cancer, 115 (2), 228-35
    DOI 10.1038/bjc.2016.194, PubMed 27351218

Publications 2015

1. Bartlett TE, Jones A, Goode EL, Fridley BL, Cunningham JM, Berns EM, Wik E, Salvesen HB, Davidson B, Trope CG, Lambrechts S, Vergote I, Widschwendter M (2015)
   Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers
   PLoS One, 10 (12), e0143178
   DOI 10.1371/journal.pone.0143178, PubMed 26629914
2. Bjørnslett M, Dahl AA, Sørebø Ø, Dørum A (2015)
   Psychological distress related to BRCA testing in ovarian cancer patients
   Fam Cancer, 14 (4), 495-504
   DOI 10.1007/s10689-015-9811-2, PubMed 25980896
3. Davidson B, Holth A, Hellesylt E, Hadar R, Katz B, Tropé CG, Reich R (2015)
   HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival
   Hum Pathol, 48, 95-101
   DOI 10.1016/j.humpath.2015.09.027, PubMed 26640230
4. du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO et al. (2015)
   Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
   Lancet Oncol, 17 (1), 78-89
   DOI 10.1016/S1470-2045(15)00366-6, PubMed 26590673
5. Katz B, Tropé CG, Reich R, Davidson B (2015)
   MicroRNAs in Ovarian Cancer
   Hum Pathol, 46 (9), 1245-56
   DOI 10.1016/j.humpath.2015.06.013, PubMed 26216350
6. Lando M, Fjeldbo CS, Wilting SM, C Snoek B, Aarnes EK, Forsberg MF, Kristensen GB, Steenbergen RD, Lyng H (2015)
   Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer
   Epigenetics, 10 (10), 970-80
   DOI 10.1080/15592294.2015.1085140, PubMed 26291246
7. Lindemann K, Cvancarova M, Eskild A (2015)
   Body mass index, diabetes and survival after diagnosis of endometrial cancer: A report from the HUNT-Survey
   Gynecol Oncol, 139 (3), 476-80
   DOI 10.1016/j.ygyno.2015.09.088, PubMed 26434365
8. Murbraech K, Solheim O, Aulie HM, Fossa SD, Aakhus S (2015)
   The impact of cisplatinum-based chemotherapy on ventricular function and cardiovascular risk factors in female survivors after malignant germ cell cancer
   ESC Heart Fail, 2 (3), 142-149
   DOI 10.1002/ehf2.12048, PubMed 28834675
9. Nymoen DA, Hetland Falkenthal TE, Holth A, Ow GS, Ivshina AV, Tropé CG, Kuznetsov VA, Staff AC, Davidson B (2015)
   Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma
   Gynecol Oncol, 139 (1), 30-9
   DOI 10.1016/j.ygyno.2015.07.107, PubMed 26232338
10. Nymoen DA, Holth A, Hetland Falkenthal TE, Tropé CG, Davidson B (2015)
    CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma
    Mol Cancer, 14, 44
    DOI 10.1186/s12943-015-0317-1, PubMed 25889687
11. Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ, ICON7 trial investigators (2015)
    Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
    Lancet Oncol, 16 (8), 928-36
    DOI 10.1016/S1470-2045(15)00086-8, PubMed 26115797
12. Ruhlmann CH, Iversen TZ, Okera M, Muhic A, Kristensen G, Feyer P, Hansen O, Herrstedt J (2015)
    Multinational study exploring patients' perceptions of side-effects induced by chemo-radiotherapy
    Radiother Oncol, 117 (2), 333-7
    DOI 10.1016/j.radonc.2015.09.014, PubMed 26372344
13. Sehouli J, Fotopoulou C, Erol E, Richter R, Reuss A, Mahner S, Lauraine EP, Kristensen G, Herrstedt J, du Bois A, Pfisterer J (2015)
    Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients
    Eur J Cancer, 51 (7), 825-32
    DOI 10.1016/j.ejca.2015.01.008, PubMed 25771433
14. Teschendorff AE, Lee SH, Jones A, Fiegl H, Kalwa M, Wagner W, Chindera K, Evans I, Dubeau L, Orjalo A, Horlings HM, Niederreiter L, Kaser A, Yang W, Goode EL, Fridley BL, Jenner RG, Berns EM, Wik E, Salvesen HB, Wisman GB, van der Zee AG, Davidson B, Trope CG, Lambrechts S et al. (2015)
    HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer
    Genome Med, 7, 108
    DOI 10.1186/s13073-015-0233-4, PubMed 26497652
15. Wiedmann M, Brunborg C, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA (2015)
    Smoking, obesity and the risk of pituitary adenoma: a large prospective cohort study (The HUNT Study)
    Eur J Epidemiol, 31 (1), 95-8
    DOI 10.1007/s10654-015-0033-6, PubMed 25903163

Publications 2014

1. Amant F, Floquet A, Friedlander M, Kristensen G, Mahner S, Nam EJ, Powell MA, Ray-Coquard I, Siddiqui N, Sykes P, Westermann AM, Seddon B (2014)
   Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma
   Int J Gynecol Cancer, 24 (9 Suppl 3), S67-72
   DOI 10.1097/IGC.0000000000000205, PubMed 25033257
2. Davidson B, Holth A, Hellesylt E, Tan TZ, Huang RY, Tropé C, Nesland JM, Thiery JP (2014)
   The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions
   Hum Pathol, 46 (1), 1-8
   DOI 10.1016/j.humpath.2014.10.004, PubMed 25455994
3. Davidson B, Nymoen DA, Elgaaen BV, Staff AC, Tropé CG, Kærn J, Reich R, Falkenthal TE (2014)
   BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma
   Virchows Arch, 464 (6), 701-7
   DOI 10.1007/s00428-014-1577-7, PubMed 24756216
4. Davidson B, Rosenfeld YB, Holth A, Hellesylt E, Tropé CG, Reich R, Yisraeli JK (2014)
   VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival
   Hum Pathol, 45 (7), 1520-8
   DOI 10.1016/j.humpath.2014.03.005, PubMed 24814803
5. Davidson B, Tropé CG (2014)
   Ovarian cancer: diagnostic, biological and prognostic aspects
   Womens Health (Lond), 10 (5), 519-33
   DOI 10.2217/whe.14.37, PubMed 25335543
6. Davidson B, Tropé CG, Reich R (2014)
   The clinical and diagnostic role of microRNAs in ovarian carcinoma
   Gynecol Oncol, 133 (3), 640-6
   DOI 10.1016/j.ygyno.2014.03.575, PubMed 24713546
7. Davidson B, Trope CG, Reich R (2014)
   The role of the tumor stroma in ovarian cancer
   Front Oncol, 4, 104
   DOI 10.3389/fonc.2014.00104, PubMed 24860785
8. Friedlander ML, Covens A, Glasspool RM, Hilpert F, Kristensen G, Kwon S, Selle F, Small W, Witteveen E, Russell P (2014)
   Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract
   Int J Gynecol Cancer, 24 (9 Suppl 3), S78-82
   DOI 10.1097/IGC.0000000000000239, PubMed 25341585
9. Hompland T, Lund KV, Ellingsen C, Kristensen GB, Rofstad EK (2014)
   Peritumoral interstitial fluid flow velocity predicts survival in cervical carcinoma
   Radiother Oncol, 113 (1), 132-8
   DOI 10.1016/j.radonc.2014.09.011, PubMed 25443501
10. Huang R, Wu D, Yuan Y, Li X, Holm R, Trope CG, Nesland JM, Suo Z (2014)
    CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients
    PLoS One, 9 (11), e112209
    DOI 10.1371/journal.pone.0112209, PubMed 25380303
11. Lindemann K, Malander S, Christensen RD, Mirza MR, Kristensen GB, Aavall-Lundqvist E, Vergote I, Rosenberg P, Boman K, Nordstrøm B (2014)
    Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
    BMC Cancer, 14, 68
    DOI 10.1186/1471-2407-14-68, PubMed 24498853
12. Micci F, Haugom L, Abeler VM, Davidson B, Tropé CG, Heim S (2014)
    Genomic profile of ovarian carcinomas
    BMC Cancer, 14, 315
    DOI 10.1186/1471-2407-14-315, PubMed 24886194
13. Micci F, Panagopoulos I, Thorsen J, Davidson B, Tropé CG, Heim S (2014)
    Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas
    PLoS Biol, 12 (2), e1001784
    DOI 10.1371/journal.pbio.1001784, PubMed 24504521
14. Nielsen B, Hveem TS, Kildal W, Abeler VM, Kristensen GB, Albregtsen F, Danielsen HE (2014)
    Entropy-based adaptive nuclear texture features are independent prognostic markers in a total population of uterine sarcomas
    Cytometry A, 87 (4), 315-25
    DOI 10.1002/cyto.a.22601, PubMed 25483227
15. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I (2014)
    Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial
    J Clin Oncol, 32 (13), 1302-8
    DOI 10.1200/JCO.2013.51.4489, PubMed 24637997
16. Sagae S, Susumu N, Viswanathan AN, Aoki D, Backes FJ, Provencher DM, Vaughan M, Creutzberg CL, Kurzeder C, Kristensen G, Lee C, Kurtz JE, Glasspool RM, Small W (2014)
    Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma
    Int J Gynecol Cancer, 24 (9 Suppl 3), S83-9
    DOI 10.1097/IGC.0000000000000264, PubMed 25341586
17. Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B, Flørenes VA (2014)
    Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions
    Gynecol Oncol, 135 (1), 118-24
    DOI 10.1016/j.ygyno.2014.07.102, PubMed 25093290
18. Smebye ML, Sveen A, Haugom L, Davidson B, Tropé CG, Lothe RA, Heim S, Skotheim RI, Micci F (2014)
    Chromosome 19 rearrangements in ovarian carcinomas: zinc finger genes are particularly targeted
    Genes Chromosomes Cancer, 53 (7), 558-67
    DOI 10.1002/gcc.22166, PubMed 24634323
19. Solheim O, Gershenson DM, Tropé CG, Rokkones E, Sun CC, Weedon-Fekjaer H, Fosså SD (2014)
    Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978-2010)
    Eur J Cancer, 50 (11), 1942-50
    DOI 10.1016/j.ejca.2014.03.288, PubMed 24857045
20. Solheim O, Tropé CG, Rokkones E, Kærn J, Paulsen T, Salvesen HB, Hagen B, Vereide AB, Fosså SD (2014)
    Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era"
    Gynecol Oncol, 136 (2), 224-9
    DOI 10.1016/j.ygyno.2014.12.010, PubMed 25511159
21. Tuft Stavnes H, Nymoen DA, Hetland Falkenthal TE, Kærn J, Tropé CG, Davidson B (2014)
    APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival
    Am J Clin Pathol, 142 (1), 51-7
    DOI 10.1309/AJCPD8NBSHXRXQL7, PubMed 24926085
22. Vaksman O, Tropé C, Davidson B, Reich R (2014)
    Exosome-derived miRNAs and ovarian carcinoma progression
    Carcinogenesis, 35 (9), 2113-20
    DOI 10.1093/carcin/bgu130, PubMed 24925027
23. Vilming Elgaaen B, Olstad OK, Haug KB, Brusletto B, Sandvik L, Staff AC, Gautvik KM, Davidson B (2014)
    Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker
    BMC Cancer, 14, 80
    DOI 10.1186/1471-2407-14-80, PubMed 24512620
24. Wang Y, Herrstedt J, Havsteen H, DePoint Christensen R, Mirza MR, Lund B, Maenpaa J, Kristensen G (2014)
    A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer
    BMC Cancer, 14, 937
    DOI 10.1186/1471-2407-14-937, PubMed 25494701

Publications 2013

1. Andersen EK, Hole KH, Lund KV, Sundfør K, Kristensen GB, Lyng H, Malinen E (2013)
   Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome
   Radiother Oncol, 107 (1), 117-22
   DOI 10.1016/j.radonc.2012.11.007, PubMed 23333024
2. Baumbusch LO, Helland Å, Wang Y, Liestøl K, Schaner ME, Holm R, Etemadmoghadam D, Alsop K, Brown P, Australian Ovarian Cancer Study Group, Mitchell G, Fereday S, DeFazio A, Bowtell DD, Kristensen GB, Lingjærde OC, Børresen-Dale AL (2013)
   High levels of genomic aberrations in serous ovarian cancers are associated with better survival
   PLoS One, 8 (1), e54356
   DOI 10.1371/journal.pone.0054356, PubMed 23372714
3. Davidson B, Abeler VM, Førsund M, Holth A, Yang Y, Kobayashi Y, Chen L, Kristensen GB, Shih IeM, Wang TL (2013)
   Gene expression signatures of primary and metastatic uterine leiomyosarcoma
   Hum Pathol, 45 (4), 691-700
   DOI 10.1016/j.humpath.2013.11.003, PubMed 24485798
4. Davidson B, Smith Y, Nesland JM, Kærn J, Reich R, Tropè CG (2013)
   Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion
   Hum Pathol, 44 (11), 2449-60
   DOI 10.1016/j.humpath.2013.06.003, PubMed 24011953
5. Greimel E, Kristensen GB, van der Burg ME, Coronado P, Rustin G, del Rio AS, Reed NS, Nordal RR, Coens C, Vergote I, European Organization for Research and Treatment of Cancer - Gynaecological Cancer Group and NCIC Clinical Trials Group (2013)
   Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy
   Gynecol Oncol, 131 (2), 437-44
   DOI 10.1016/j.ygyno.2013.08.014, PubMed 23994107
6. Lando M, Wilting SM, Snipstad K, Clancy T, Bierkens M, Aarnes EK, Holden M, Stokke T, Sundfør K, Holm R, Kristensen GB, Steenbergen RD, Lyng H (2013)
   Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling
   J Pathol, 230 (1), 59-69
   DOI 10.1002/path.4168, PubMed 23335387
7. Onsrud M, Cvancarova M, Hellebust TP, Tropé CG, Kristensen GB, Lindemann K (2013)
   Long-term outcomes after pelvic radiation for early-stage endometrial cancer
   J Clin Oncol, 31 (31), 3951-6
   DOI 10.1200/JCO.2013.48.8023, PubMed 24019546
8. Solheim O, Kærn J, Tropé CG, Rokkones E, Dahl AA, Nesland JM, Fosså SD (2013)
   Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009)
   Gynecol Oncol, 131 (2), 330-5
   DOI 10.1016/j.ygyno.2013.08.028, PubMed 24001518
9. Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian W, Swart AM, Oza A, Perren T (2013)
   Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
   Lancet Oncol, 14 (3), 236-43
   DOI 10.1016/S1470-2045(12)70567-3, PubMed 23333117
10. Stavnes HT, Holth A, Don T, Kærn J, Vaksman O, Reich R, Trope' CG, Davidson B (2013)
    HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival
    Gynecol Oncol, 129 (2), 358-63
    DOI 10.1016/j.ygyno.2013.02.021, PubMed 23438671
11. Vaksman O, Davidson B, Tropé C, Reich R (2013)
    Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases
    Hum Pathol, 44 (12), 2677-83
    DOI 10.1016/j.humpath.2013.07.009, PubMed 24060004
12. Vettukattil R, Hetland TE, Flørenes VA, Kærn J, Davidson B, Bathen TF (2013)
    Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma
    Hum Pathol, 44 (9), 1859-66
    DOI 10.1016/j.humpath.2013.02.009, PubMed 23656974

Publications 2012

1. Bjørnslett M, Knappskog S, Lønning PE, Dørum A (2012)
   Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers
   BMC Cancer, 12, 454
   DOI 10.1186/1471-2407-12-454, PubMed 23039163
2. Brusegard K, Stavnes HT, Nymoen DA, Flatmark K, Trope CG, Davidson B (2012)
   Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma
   Virchows Arch, 460 (2), 193-202
   DOI 10.1007/s00428-011-1191-x, PubMed 22249560
3. Davidson B, Abeler VM, Hellesylt E, Holth A, Shih IeM, Skeie-Jensen T, Chen L, Yang Y, Wang TL (2012)
   Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma
   Gynecol Oncol, 128 (2), 349-55
   DOI 10.1016/j.ygyno.2012.11.021, PubMed 23178314
4. Davidson B, Holth A, Nguyen MT, Tropé CG, Wu C (2012)
   Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases
   Gynecol Oncol, 128 (2), 364-70
   DOI 10.1016/j.ygyno.2012.10.015, PubMed 23099104
5. Davidson B, Tropé CG, Reich R (2012)
   Epithelial-mesenchymal transition in ovarian carcinoma
   Front Oncol, 2, 33
   DOI 10.3389/fonc.2012.00033, PubMed 22655269
6. Elgaaen BV, Olstad OK, Sandvik L, Odegaard E, Sauer T, Staff AC, Gautvik KM (2012)
   ZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas and correlate with survival
   PLoS One, 7 (9), e46317
   DOI 10.1371/journal.pone.0046317, PubMed 23029477
7. Elstrand MB, Sandstad B, Oksefjell H, Davidson B, Tropé CG (2012)
   Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective
   Acta Obstet Gynecol Scand, 91 (3), 308-17
   DOI 10.1111/j.1600-0412.2011.01316.x, PubMed 22050605
8. Fotopoulou C, Zang R, Gultekin M, Cibula D, Ayhan A, Liu D, Richter R, Braicu I, Mahner S, Harter P, Trillsch F, Kumar S, Peiretti M, Dowdy SC, Maggioni A, Trope C, Sehouli J (2012)
   Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation
   Ann Surg Oncol, 20 (4), 1348-54
   DOI 10.1245/s10434-012-2673-z, PubMed 23054114
9. Gillet JP, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R, Kamat AA, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MM (2012)
   Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma
   Clin Cancer Res, 18 (11), 3197-206
   DOI 10.1158/1078-0432.CCR-12-0056, PubMed 22492981
10. Halle C, Andersen E, Lando M, Aarnes EK, Hasvold G, Holden M, Syljuåsen RG, Sundfør K, Kristensen GB, Holm R, Malinen E, Lyng H (2012)
    Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI
    Cancer Res, 72 (20), 5285-95
    DOI 10.1158/0008-5472.CAN-12-1085, PubMed 22890239
11. Hetland TE, Holth A, Kærn J, Flørenes VA, Tropé CG, Davidson B (2012)
    HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases
    Virchows Arch, 460 (5), 505-13
    DOI 10.1007/s00428-012-1228-9, PubMed 22476403
12. Hetland TE, Kærn J, Skrede M, Sandstad B, Tropé C, Davidson B, Flørenes VA (2012)
    Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
    Cancer Chemother Pharmacol, 69 (5), 1307-14
    DOI 10.1007/s00280-012-1835-9, PubMed 22302409
13. Hetland TE, Nymoen DA, Emilsen E, Kærn J, Tropé CG, Flørenes VA, Davidson B (2012)
    MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival
    Gynecol Oncol, 126 (3), 460-5
    DOI 10.1016/j.ygyno.2012.05.029, PubMed 22652154
14. Hetland TE, Nymoen DA, Holth A, Brusegard K, Flørenes VA, Kærn J, Tropé CG, Davidson B (2012)
    Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance
    Hum Pathol, 44 (5), 777-85
    DOI 10.1016/j.humpath.2012.08.002, PubMed 23114921
15. Kaye S, Aamdal S, Jones R, Freyer G, Pujade-Lauraine E, de Vries EG, Barriuso J, Sandhu S, Tan DS, Hartog V, Kuenen B, Ruijter R, Kristensen GB, Nyakas M, Barrett S, Burke W, Pietersma D, Stuart M, Emeribe U, Boven E (2012)
    Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
    Br J Cancer, 106 (11), 1728-34
    DOI 10.1038/bjc.2012.158, PubMed 22531637
16. Knappskog S, Gansmo LB, Romundstad P, Bjørnslett M, Trovik J, Sommerfelt-Pettersen J, Løkkevik E, Norwegian Breast Cancer Group trial NBCG VI, Tollenaar RA, Seynaeve C, Devilee P, Salvesen HB, Dørum A, Hveem K, Vatten L, Lønning PE (2012)
    MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk
    PLoS One, 7 (4), e36263
    DOI 10.1371/journal.pone.0036263, PubMed 22558411
17. Lee CK, Simes RJ, Brown C, Gebski V, Pfisterer J, Swart AM, Berton-Rigaud D, Plante M, Skeie-Jensen T, Vergote I, Schauer C, Pisano C, Parma G, Baumann K, Ledermann JA, Pujade-Lauraine E, Bentley J, Kristensen G, Belau A, Nankivell M, Canzler U, Lord SJ, Kurzeder C, Friedlander M (2012)
    A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer
    Ann Oncol, 24 (4), 937-43
    DOI 10.1093/annonc/mds538, PubMed 23104722
18. Liang D, Ma Y, Liu J, Trope CG, Holm R, Nesland JM, Suo Z (2012)
    The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells
    BMC Cancer, 12, 201
    DOI 10.1186/1471-2407-12-201, PubMed 22642602
19. Lindemann K, Christensen RD, Vergote I, Stuart G, Izquierdo MA, Kærn J, Havsteen H, Eisenhauer E, Ridderheim M, Lopez AB, Hirte H, Aavall-Lundquvist E, Vrdoljak E, Green J, Kristensen GB (2012)
    First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG
    Ann Oncol, 23 (10), 2613-9
    DOI 10.1093/annonc/mds060, PubMed 22539562
20. Michelsen TM, Dørum A, Cvancarova M, Liavaag AH, Dahl AA (2012)
    Association between hysterectomy with ovarian preservation and cardiovascular disease in a Norwegian population-based sample
    Gynecol Obstet Invest, 75 (1), 61-7
    DOI 10.1159/000345072, PubMed 23220872
21. Nielsen B, Albregtsen F, Kildal W, Abeler VM, Kristensen GB, Danielsen HE (2012)
    The prognostic value of adaptive nuclear texture features from patient gray level entropy matrices in early stage ovarian cancer
    Anal Cell Pathol (Amst), 35 (4), 305-14
    DOI 10.3233/ACP-2012-0065, PubMed 22596183
22. Pradhan M, Davidson B, Abeler VM, Danielsen HE, Tropé CG, Kristensen GB, Risberg BÅ (2012)
    DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium
    Virchows Arch, 461 (3), 291-8
    DOI 10.1007/s00428-012-1275-2, PubMed 22824999
23. Tropé CG, Abeler VM, Kristensen GB (2012)
    Diagnosis and treatment of sarcoma of the uterus. A review
    Acta Oncol, 51 (6), 694-705
    DOI 10.3109/0284186X.2012.689111, PubMed 22793037
24. Tropé CG, Elstrand MB, Sandstad B, Davidson B, Oksefjell H (2012)
    Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
    Eur J Cancer, 48 (14), 2146-54
    DOI 10.1016/j.ejca.2012.01.031, PubMed 22382201
25. Tropé CG, Kaern J, Davidson B (2012)
    Borderline ovarian tumours
    Best Pract Res Clin Obstet Gynaecol, 26 (3), 325-36
    DOI 10.1016/j.bpobgyn.2011.12.006, PubMed 22321906
26. Vaksman O, Hetland TE, Trope' CG, Reich R, Davidson B (2012)
    Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma
    Hum Pathol, 43 (11), 2062-9
    DOI 10.1016/j.humpath.2012.02.016, PubMed 22647351
27. Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, Bonaventura T, Vergote I, Piccirillo MC, Fossati R, Gebski V, Lauraine EP (2012)
    Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
    Br J Cancer, 107 (4), 588-91
    DOI 10.1038/bjc.2012.307, PubMed 22836511
28. Weiss I, Trope CG, Reich R, Davidson B (2012)
    Hyaluronan synthase and hyaluronidase expression in serous ovarian carcinoma is related to anatomic site and chemotherapy exposure
    Int J Mol Sci, 13 (10), 12925-38
    DOI 10.3390/ijms131012925, PubMed 23202930

Publications 2011

1. Andersen EK, Hole KH, Lund KV, Sundfør K, Kristensen GB, Lyng H, Malinen E (2011)
   Dynamic contrast-enhanced MRI of cervical cancers: temporal percentile screening of contrast enhancement identifies parameters for prediction of chemoradioresistance
   Int J Radiat Oncol Biol Phys, 82 (3), e485-92
   DOI 10.1016/j.ijrobp.2011.05.050, PubMed 22014954
2. Andersen EK, Kristensen GB, Lyng H, Malinen E (2011)
   Pharmacokinetic analysis and k-means clustering of DCEMR images for radiotherapy outcome prediction of advanced cervical cancers
   Acta Oncol, 50 (6), 859-65
   DOI 10.3109/0284186X.2011.578586, PubMed 21767185
3. Bock AJ, Dong HP, Tropé CG, Staff AC, Risberg B, Davidson B (2011)
   Nucleoside transporters are widely expressed in ovarian carcinoma effusions
   Cancer Chemother Pharmacol, 69 (2), 467-75
   DOI 10.1007/s00280-011-1716-7, PubMed 21822668
4. Bock AJ, Nymoen DA, Brenne K, Kærn J, Davidson B (2011)
   SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions
   Hum Pathol, 43 (5), 669-74
   DOI 10.1016/j.humpath.2011.06.003, PubMed 21855113
5. Bock AJ, Tuft Stavnes H, Kærn J, Berner A, Staff AC, Davidson B (2011)
   Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status
   Tumour Biol, 32 (3), 589-96
   DOI 10.1007/s13277-011-0157-6, PubMed 21350924
6. Brenne K, Nymoen DA, Hetland TE, Trope' CG, Davidson B (2011)
   Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival
   Hum Pathol, 43 (4), 496-505
   DOI 10.1016/j.humpath.2011.05.023, PubMed 21855111
7. Dahl AA, Gudbergsson SB, Dørum A, Fosså SD, Liavaag AH, Sørebø Ø (2011)
   "The impact of cancer scale" version 1: psychometric testing of the Norwegian translation in a heterogeneous sample of cancer survivors
   Qual Life Res, 21 (8), 1459-70
   DOI 10.1007/s11136-011-0053-y, PubMed 22045155
8. Davidson B, Holth A, Moripen L, Trope' CG, Shih IeM (2011)
   Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome
   Hum Pathol, 42 (7), 991-7
   DOI 10.1016/j.humpath.2010.10.013, PubMed 21315424
9. Dong HP, Ree Rosnes AK, Bock AJ, Holth A, Flørenes VA, Trope' CG, Risberg B, Davidson B (2011)
   Flow cytometric measurement of cellular FLICE-inhibitory protein (c-FLIP) in ovarian carcinoma effusions
   Cytopathology, 22 (6), 373-82
   DOI 10.1111/j.1365-2303.2011.00929.x, PubMed 22032542
10. Elstrand MB, Stavnes HT, Tropé CG, Davidson B (2011)
    Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions
    Hum Pathol, 43 (4), 529-35
    DOI 10.1016/j.humpath.2011.05.022, PubMed 21864883
11. Gillet JP, Wang J, Calcagno AM, Green LJ, Varma S, Bunkholt Elstrand M, Trope CG, Ambudkar SV, Davidson B, Gottesman MM (2011)
    Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions
    Mol Pharm, 8 (6), 2080-8
    DOI 10.1021/mp200240a, PubMed 21761824
12. Gultekin M, Dursun P, Vranes B, Laky R, Bossart M, Grabowski JP, Piek JM, Manchanda R, Grimm C, Dallaku K, Babloyan S, Moisei A, Van Gorp T, Cadron I, Markov P, Micevska A, Halaska M, Steffensen KD, Gristsenko L, Nissi R, Lambaudie E, Tsitsishvili Z, Haidopoulos D, Tsolakidis D, Novak Z et al. (2011)
    Gynecologic oncology training systems in Europe: a report from the European network of young gynaecological oncologists
    Int J Gynecol Cancer, 21 (8), 1500-6
    DOI 10.1097/IGC.0b013e3182202d17, PubMed 21720256
13. Halle C, Lando M, Sundfør K, Kristensen GB, Holm R, Lyng H (2011)
    Phosphorylation of EGFR measured with in situ proximity ligation assay: relationship to EGFR protein level and gene dosage in cervical cancer
    Radiother Oncol, 101 (1), 152-7
    DOI 10.1016/j.radonc.2011.05.052, PubMed 21680035
14. Halle C, Lando M, Svendsrud DH, Clancy T, Holden M, Sundfør K, Kristensen GB, Holm R, Lyng H (2011)
    Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer
    Clin Cancer Res, 17 (16), 5501-12
    DOI 10.1158/1078-0432.CCR-11-0297, PubMed 21737508
15. Hetland TE, Hellesylt E, Flørenes VA, Tropé C, Davidson B, Kærn J (2011)
    Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance
    Hum Pathol, 42 (7), 1019-26
    DOI 10.1016/j.humpath.2010.10.025, PubMed 21315408
16. Kildal W, Micci F, Risberg B, Abeler VM, Kristensen GB, Heim S, Danielsen HE (2011)
    Genomic imbalances in endometrial adenocarcinomas - comparison of DNA ploidy, karyotyping and comparative genomic hybridization
    Mol Oncol, 6 (1), 98-107
    DOI 10.1016/j.molonc.2011.10.002, PubMed 22062770
17. Kim G, Davidson B, Henning R, Wang J, Yu M, Annunziata C, Hetland T, Kohn EC (2011)
    Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome
    Cancer, 118 (6), 1543-53
    DOI 10.1002/cncr.26449, PubMed 22009736
18. Knappskog S, Bjørnslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H, Guo Y, Zhang X, Yang M, Ylisaukko-Oja SK, Alhopuro P, Arola J, Tollenaar RA, van Asperen CJ, Seynaeve C, Staalesen V, Chrisanthar R, Løkkevik E, Salvesen HB, Evans DG, Newman WG, Lin D, Aaltonen LA, Børresen-Dale AL, Tell GS et al. (2011)
    The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians
    Cancer Cell, 19 (2), 273-82
    DOI 10.1016/j.ccr.2010.12.019, PubMed 21316605
19. Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E, Gynecologic Cancer Intergroup (2011)
    Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study
    Ann Oncol, 22 (11), 2417-23
    DOI 10.1093/annonc/mdr001, PubMed 21402619
20. Oksefjell H, Sandstad B, Tropé C (2011)
    The role of surgery in the second relapse of epithelial ovarian cancer. Selection criteria, morbidity and survival outcome
    Eur J Gynaecol Oncol, 32 (4), 369-76
    PubMed 21941955
21. Paulsen T, Kærn J, Tropé C (2011)
    Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery
    Gynecol Oncol, 122 (1), 83-8
    DOI 10.1016/j.ygyno.2011.02.038, PubMed 21435701
22. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK et al. (2011)
    A phase 3 trial of bevacizumab in ovarian cancer
    N Engl J Med, 365 (26), 2484-96
    DOI 10.1056/NEJMoa1103799, PubMed 22204725
23. Pradhan M, Abeler VM, Danielsen HE, Sandstad B, Tropé CG, Kristensen GB, Risberg BÅ (2011)
    Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium
    Ann Oncol, 23 (5), 1178-84
    DOI 10.1093/annonc/mdr368, PubMed 21965471
24. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J, Gynecological Cancer Intergroup (2011)
    Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)
    Int J Gynecol Cancer, 21 (2), 419-23
    DOI 10.1097/IGC.0b013e3182070f17, PubMed 21270624
25. Sert MB, Abeler V (2011)
    Robot-assisted laparoscopic radical hysterectomy: comparison with total laparoscopic hysterectomy and abdominal radical hysterectomy; one surgeon's experience at the Norwegian Radium Hospital
    Gynecol Oncol, 121 (3), 600-4
    DOI 10.1016/j.ygyno.2011.02.002, PubMed 21353294
26. Thigpen T, duBois A, McAlpine J, DiSaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Poveda A, Rubinstein L, Bacon M, Kitchener H, Stuart GC, Gynecologic Cancer InterGroup (2011)
    First-line therapy in ovarian cancer trials
    Int J Gynecol Cancer, 21 (4), 756-62
    DOI 10.1097/IGC.0b013e31821ce75d, PubMed 21543937
27. Tian WJ, Chi DS, Sehouli J, Tropé CG, Jiang R, Ayhan A, Cormio G, Xing Y, Breitbach GP, Braicu EI, Rabbitt CA, Oksefjell H, Fotopoulou C, Meerpohl HG, du Bois A, Berek JS, Zang RY, Harter P (2011)
    A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection
    Ann Surg Oncol, 19 (2), 597-604
    DOI 10.1245/s10434-011-1873-2, PubMed 21732142
28. Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B, Reich R (2011)
    miRNA profiling along tumour progression in ovarian carcinoma
    J Cell Mol Med, 15 (7), 1593-602
    DOI 10.1111/j.1582-4934.2010.01148.x, PubMed 20716115
29. Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A (2011)
    Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer
    Eur J Cancer, 47 Suppl 3, S88-92
    DOI 10.1016/S0959-8049(11)70152-6, PubMed 21944035
30. Vergote I, Tropé CG, Amant F, Ehlen T, Reed NS, Casado A (2011)
    Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer
    J Clin Oncol, 29 (31), 4076-8
    DOI 10.1200/JCO.2011.36.9785, PubMed 21931032
31. Vistad I, Cvancarova M, Kristensen GB, Fosså SD (2011)
    A study of chronic pelvic pain after radiotherapy in survivors of locally advanced cervical cancer
    J Cancer Surviv, 5 (2), 208-16
    DOI 10.1007/s11764-011-0172-z, PubMed 21259075
32. Zang RY, Harter P, Chi DS, Sehouli J, Jiang R, Tropé CG, Ayhan A, Cormio G, Xing Y, Wollschlaeger KM, Braicu EI, Rabbitt CA, Oksefjell H, Tian WJ, Fotopoulou C, Pfisterer J, du Bois A, Berek JS (2011)
    Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
    Br J Cancer, 105 (7), 890-6
    DOI 10.1038/bjc.2011.328, PubMed 21878937

Publications 2010

1. Bock AJ, Stavnes HT, Kempf T, Tropè CG, Berner A, Davidson B, Staff AC (2010)
   Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions
   Int J Gynecol Cancer, 20 (9), 1448-55
   DOI 10.1111/IGC.0b013e3181f7d6be, PubMed 21336029
2. Bunkholt Elstrand M, Dong HP, Ødegaard E, Holth A, Elloul S, Reich R, Tropé CG, Davidson B (2010)
   Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma
   Hum Pathol, 41 (6), 794-804
   DOI 10.1016/j.humpath.2009.09.017, PubMed 20153512
3. Davidson B, Reich R, Trope CG, Wang TL, Shih IeM (2010)
   New determinates of disease progression and outcome in metastatic ovarian carcinoma
   Histol Histopathol, 25 (12), 1591-609
   DOI 10.14670/HH-25.1591, PubMed 20886439
4. du Bois A, Herrstedt J, Hardy-Bessard AC, Müller HH, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Sehouli J (2010)
   Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
   J Clin Oncol, 28 (27), 4162-9
   DOI 10.1200/JCO.2009.27.4696, PubMed 20733132
5. Elgaaen BV, Haug KB, Wang J, Olstad OK, Fortunati D, Onsrud M, Staff AC, Sauer T, Gautvik KM (2010)
   POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas
   PLoS One, 5 (11), e13837
   DOI 10.1371/journal.pone.0013837, PubMed 21079801
6. Elloul S, Vaksman O, Stavnes HT, Trope CG, Davidson B, Reich R (2010)
   Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions
   Clin Exp Metastasis, 27 (3), 161-72
   DOI 10.1007/s10585-010-9315-2, PubMed 20213325
7. Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, Andersson H, Grenman S, Lundgren C, Rosenberg P, Boman K, Tholander B, Scambia G, Reed N, Cormio G, Tognon G, Clarke J, Sawicki T, Zola P, Kristensen G (2010)
   Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies
   Eur J Cancer, 46 (13), 2422-31
   DOI 10.1016/j.ejca.2010.06.002, PubMed 20619634
8. Hovland S, Arbyn M, Lie AK, Ryd W, Borge B, Berle EJ, Skomedal H, Kadima TM, Kyembwa L, Billay EM, Mukwege D, Chirimwami RB, Mvula TM, Snijders PJ, Meijer CJ, Karlsen F (2010)
   A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo
   Br J Cancer, 102 (6), 957-65
   DOI 10.1038/sj.bjc.6605594, PubMed 20197765
9. Micci F, Haugom L, Ahlquist T, Andersen HK, Abeler VM, Davidson B, Trope CG, Lothe RA, Heim S (2010)
   Genomic aberrations in borderline ovarian tumors
   J Transl Med, 8, 21
   DOI 10.1186/1479-5876-8-21, PubMed 20184781
10. Micci F, Skotheim RI, Haugom L, Weimer J, Eibak AM, Abeler VM, Trope CG, Arnold N, Lothe RA, Heim S (2010)
    Array-CGH analysis of microdissected chromosome 19 markers in ovarian carcinoma identifies candidate target genes
    Genes Chromosomes Cancer, 49 (11), 1046-53
    DOI 10.1002/gcc.20813, PubMed 20725991
11. Michelsen TM, Tonstad S, Pripp AH, Tropé CG, Dørum A (2010)
    Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer
    Int J Gynecol Cancer, 20 (2), 233-9
    DOI 10.1111/igc.0b013e3181ca5ff4, PubMed 20169665
12. Park JT, Chen X, Tropè CG, Davidson B, Shih IeM, Wang TL (2010)
    Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin
    Am J Pathol, 177 (3), 1087-94
    DOI 10.2353/ajpath.2010.100316, PubMed 20671266
13. Pradhan M, Abeler VM, Davidson B, Kildal W, Nybøen A, Tropé CG, Risberg B, Danielsen HE (2010)
    DNA ploidy heterogeneity in endometrial carcinoma: comparison between curettage and hysterectomy specimens
    Int J Gynecol Pathol, 29 (6), 572-8
    DOI 10.1097/PGP.0b013e3181e2e8ee, PubMed 20881853
14. Pradhan M, Risberg BA, Tropé CG, van de Rijn M, Gilks CB, Lee CH (2010)
    Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation
    BMC Cancer, 10, 493
    DOI 10.1186/1471-2407-10-493, PubMed 20843305
15. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A (2010)
    Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse
    J Clin Oncol, 28 (20), 3323-9
    DOI 10.1200/JCO.2009.25.7519, PubMed 20498395
16. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM, MRC OV05, EORTC 55955 investigators (2010)
    Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
    Lancet, 376 (9747), 1155-63
    DOI 10.1016/S0140-6736(10)61268-8, PubMed 20888993
17. Sert B (2010)
    Robotic port-site and pelvic recurrences after robot-assisted laparoscopic radical hysterectomy for a stage IB1 adenocarcinoma of the cervix with negative lymph nodes
    Int J Med Robot, 6 (2), 132-5
    DOI 10.1002/rcs.295, PubMed 20049750
18. Sert MB (2010)
    Comparison between robot-assisted laparoscopic radical hysterectomy (RRH) and abdominal radical hysterectomy (ARH): a case control study from EIO/Milan
    Gynecol Oncol, 117 (2), 389; author reply 389-90
    DOI 10.1016/j.ygyno.2010.01.032, PubMed 20153028
19. Tropé CG (2010)
    Management of cervical carcinoma stage IV: comment.
    CME Journal of Gynecologic Oncology, 15 (1), 69-71
    PublikaID 105
20. Tropé CG, Kristensen GB (2010)
    The treatment of recurrent cervical cancer
    CME Journal of Gynecologic Oncology, 15 (1), 72-90
    PublikaID 106
21. Tropé CG, Kristensen GB (2010)
    Surgery in treatment of recurrent cervical cancer
    CME Journal of Gynecologic Oncology, 15 (1), 33-39
    PublikaID 104
22. Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Creutzberg C, Del Campo J, Siddiqui N, Calvert P, Bamias A, Tulunay G, van der Zee AG, du Bois A, European Network of Gynaecological Oncological Trial Groups (2010)
    European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies
    Int J Gynecol Cancer, 20 (3), 476-8
    DOI 10.1111/IGC.0b013e3181d3caa8, PubMed 20375816
23. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS, European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group, NCIC Clinical Trials Group (2010)
    Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
    N Engl J Med, 363 (10), 943-53
    DOI 10.1056/NEJMoa0908806, PubMed 20818904
24. Verleye L, Ottevanger PB, Kristensen GB, Ehlen T, Johnson N, van der Burg ME, Reed NS, Verheijen RH, Gaarenstroom KN, Mosgaard B, Seoane JM, van der Velden J, Lotocki R, van der Graaf W, Penninckx B, Coens C, Stuart G, Vergote I (2010)
    Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial
    Eur J Cancer, 47 (1), 57-64
    DOI 10.1016/j.ejca.2010.08.008, PubMed 20850296
25. Wang Z, Trope CG, Flørenes VA, Suo Z, Nesland JM, Holm R (2010)
    Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
    BMC Cancer, 10, 233
    DOI 10.1186/1471-2407-10-233, PubMed 20500813
26. Yuan Y, Leszczynska M, Konstantinovsky S, Tropé CG, Reich R, Davidson B (2010)
    Netrin-4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors
    Diagn Cytopathol, 39 (8), 562-6
    DOI 10.1002/dc.21424, PubMed 20730893

Publications 2009

1. Abeler VM, Røyne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB (2009)
   Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients
   Histopathology, 54 (3), 355-64
   DOI 10.1111/j.1365-2559.2009.03231.x, PubMed 19236512
2. Baekelandt MM, Castiglione M, ESMO Guidelines Working Group (2009)
   Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up
   Ann Oncol, 20 Suppl 4, 29-31
   DOI 10.1093/annonc/mdp120, PubMed 19454455
3. Davidson B, Hadar R, Stavnes HT, Trope' CG, Reich R (2009)
   Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival
   Hum Pathol, 40 (5), 705-13
   DOI 10.1016/j.humpath.2008.09.019, PubMed 19157507
4. Dong HP, Holth A, Kleinberg L, Ruud MG, Elstrand MB, Tropé CG, Davidson B, Risberg B (2009)
   Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters
   Am J Clin Pathol, 132 (5), 756-62
   DOI 10.1309/AJCPAVFA8J3KHPRS, PubMed 19846818
5. Elstrand MB, Kleinberg L, Kohn EC, Tropé CG, Davidson B (2009)
   Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma
   Int J Gynecol Pathol, 28 (3), 211-21
   DOI 10.1097/PGP.0b013e31818b0f5e, PubMed 19620938
6. Kildal W, Pradhan M, Abeler VM, Kristensen GB, Danielsen HE (2009)
   Beta-catenin expression in uterine sarcomas and its relation to clinicopathological parameters
   Eur J Cancer, 45 (13), 2412-7
   DOI 10.1016/j.ejca.2009.06.017, PubMed 19622417
7. Knopp S, Tropè C, Nesland JM, Holm R (2009)
   A review of molecular pathological markers in vulvar carcinoma: lack of application in clinical practice
   J Clin Pathol, 62 (3), 212-8
   DOI 10.1136/jcp.2008.057240, PubMed 19251952
8. Lando M, Holden M, Bergersen LC, Svendsrud DH, Stokke T, Sundfør K, Glad IK, Kristensen GB, Lyng H (2009)
   Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer
   PLoS Genet, 5 (11), e1000719
   DOI 10.1371/journal.pgen.1000719, PubMed 19911042
9. Liavaag AH, Dørum A, Fosså SD, Tropé C, Dahl AA (2009)
   Morbidity associated with "self-rated health" in epithelial ovarian cancer survivors
   BMC Cancer, 9, 2
   DOI 10.1186/1471-2407-9-2, PubMed 19121203
10. Liavaag AH, Tonstad S, Pripp AH, Tropé C, Dørum A (2009)
    Prevalence and determinants of metabolic syndrome and elevated Framingham risk score in epithelial ovarian cancer survivors: a controlled observational study
    Int J Gynecol Cancer, 19 (4), 634-40
    DOI 10.1111/IGC.0b013e3181a13058, PubMed 19509562
11. Micci F, Haugom L, Ahlquist T, Abeler VM, Trope CG, Lothe RA, Heim S (2009)
    Tumor spreading to the contralateral ovary in bilateral ovarian carcinoma is a late event in clonal evolution
    J Oncol, 2010, 646340
    DOI 10.1155/2010/646340, PubMed 19759843
12. Michelsen TM, Dørum A, Dahl AA (2009)
    A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer
    Gynecol Oncol, 113 (1), 128-33
    DOI 10.1016/j.ygyno.2008.12.024, PubMed 19178933
13. Michelsen TM, Dørum A, Tropé CG, Fosså SD, Dahl AA (2009)
    Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer
    Int J Gynecol Cancer, 19 (6), 1029-36
    DOI 10.1111/IGC.0b013e3181a83cd5, PubMed 19820364
14. Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, Børresen-Dale AL, Mills GB (2009)
    Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis
    PLoS One, 4 (5), e5583
    DOI 10.1371/journal.pone.0005583, PubMed 19440550
15. Pradhan M, Davidson B, Tropé CG, Danielsen HE, Abeler VM, Risberg B (2009)
    Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications
    Virchows Arch, 454 (6), 677-83
    DOI 10.1007/s00428-009-0778-y, PubMed 19421773
16. Sert MB (2009)
    Robot assisted laparoscopic radical hysterectomy and pelvic lymphadenectomy with short and long term morbidity
    Gynecol Oncol, 115 (1), 164-165
    DOI 10.1016/j.ygyno.2009.05.028, PubMed 19539356
17. Sert MB, Eraker R (2009)
    Robot-assisted laparoscopic surgery in gynaecological oncology; initial experience at Oslo Radium Hospital and 16 months follow-up
    Int J Med Robot, 5 (4), 410-4
    DOI 10.1002/rcs.272, PubMed 19569081
18. Tropé C, Davidson B, Paulsen T, Abeler VM, Kaern J (2009)
    Diagnosis and treatment of borderline ovarian neoplasms "the state of the art"
    Eur J Gynaecol Oncol, 30 (5), 471-82
    PubMed 19899396
19. Tropé C, Iversen OE (2009)
    [From wonder to alarm--the Tidsskriftet, the Nobel Prize and the HPV vaccine]
    Tidsskr Nor Laegeforen, 129 (7), 651; author reply 651
    DOI 10.4045/tidsskr.09.0067, PubMed 19337352
20. Walker KJ, McGrattan K, Aas-Eng K, Smith AF (2009)
    Ultrasound guidance for peripheral nerve blockade
    Cochrane Database Syst Rev (4), CD006459
    DOI 10.1002/14651858.CD006459.pub2, PubMed 19821368
21. Yuan Y, Nymoen DA, Dong HP, Bjørang O, Shih IeM, Low PS, Trope' CG, Davidson B (2009)
    Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions
    Hum Pathol, 40 (10), 1453-60
    DOI 10.1016/j.humpath.2009.02.013, PubMed 19454358

Publications 2008

1. Baekelandt MM, Castiglione M, ESMO Guidelines Working Group (2008)
   Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up
   Ann Oncol, 19 Suppl 2, ii19-20
   DOI 10.1093/annonc/mdn113, PubMed 18456753
2. Box I, Marrannes J, De Peuter B, Baekelandt M (2008)
   Large mammographic opacity due to hamartoma
   JBR-BTR, 91 (4), 177
   PubMed 18817100
3. Dong HP, Kleinberg L, Silins I, Flørenes VA, Tropé CG, Risberg B, Nesland JM, Davidson B (2008)
   Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma
   Cancer, 112 (1), 84-93
   DOI 10.1002/cncr.23140, PubMed 17985388
4. Dørum A, Tonstad S, Liavaag AH, Michelsen TM, Hildrum B, Dahl AA (2008)
   Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2)
   Gynecol Oncol, 109 (3), 377-83
   DOI 10.1016/j.ygyno.2008.02.025, PubMed 18407340
5. Evans DG, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dørum A, Steel M, Lalloo F, Apold J, Porteous ME, Vasen HF, van Asperen CJ, Moller P (2008)
   Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers
   J Med Genet, 46 (9), 593-7
   DOI 10.1136/jmg.2008.058248, PubMed 18413372
6. Holm R, de Putte GV, Suo Z, Lie AK, Kristensen GB (2008)
   Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis
   Int J Med Sci, 5 (3), 121-6
   DOI 10.7150/ijms.5.121, PubMed 18566674
7. Holm R, Kraus I, Skomedal H, Langerød A, Kristensen GB, Lyng H (2008)
   Human papillomavirus DNA and e6/e7 mRNA status in relation to survival of patients treated for cervical squamous cell carcinoma
   Open Virol J, 2, 74-81
   DOI 10.2174/1874357900802010074, PubMed 19440467
8. Kleinberg L, Holth A, Trope CG, Reich R, Davidson B (2008)
   Claudin upregulation in ovarian carcinoma effusions is associated with poor survival
   Hum Pathol, 39 (5), 747-57
   DOI 10.1016/j.humpath.2007.10.002, PubMed 18439941
9. Kleinberg L, Pradhan M, Tropé CG, Nesland JM, Davidson B, Risberg B (2008)
   Ovarian carcinoma cells in effusions show increased S-phase fraction compared to corresponding primary tumors
   Diagn Cytopathol, 36 (9), 637-44
   DOI 10.1002/dc.20879, PubMed 18677760
10. Knopp S, Nesland JM, Tropé C (2008)
    SLNB and the importance of micrometastases in vulvar squamous cell carcinoma
    Surg Oncol, 17 (3), 219-25
    DOI 10.1016/j.suronc.2008.05.001, PubMed 18556194
11. Lhommé C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, Manikhas GM, Baekelandt MM, Gordon AN, Fracasso PM, Mietlowski WL, Jones GJ, Dugan MH (2008)
    Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer
    J Clin Oncol, 26 (16), 2674-82
    DOI 10.1200/JCO.2007.14.9807, PubMed 18509179
12. Lyng H, Lando M, Brøvig RS, Svendsrud DH, Johansen M, Galteland E, Brustugun OT, Meza-Zepeda LA, Myklebost O, Kristensen GB, Hovig E, Stokke T (2008)
    GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data
    Genome Biol, 9 (5), R86
    DOI 10.1186/gb-2008-9-5-r86, PubMed 18500990
13. Micci F, Haugom L, Abeler VM, Tropé CG, Danielsen HE, Heim S (2008)
    Consistent numerical chromosome aberrations in thecofibromas of the ovary
    Virchows Arch, 452 (3), 269-76
    DOI 10.1007/s00428-007-0561-x, PubMed 18188592
14. Michelsen TM, Pripp AH, Tonstad S, Tropé CG, Dørum A (2008)
    Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study
    Eur J Cancer, 45 (1), 82-9
    DOI 10.1016/j.ejca.2008.09.028, PubMed 19008092
15. Oksefjell H, Sandstad B, Tropé C (2008)
    The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer
    Ann Oncol, 20 (2), 286-93
    DOI 10.1093/annonc/mdn591, PubMed 18725390
16. Oksefjell H, Sandstad B, Tropé C (2008)
    Is the watch and wait approach adequate after comprehensive surgical staging in invasive stage I epithelial ovarian cancer? The Norwegian Radium Hospital experience
    Eur J Gynaecol Oncol, 29 (6), 583-9
    PubMed 19115683
17. Vistad I, Cvancarova M, Fosså SD, Kristensen GB (2008)
    Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: how well do physicians' assessments agree with those of their patients?
    Int J Radiat Oncol Biol Phys, 71 (5), 1335-42
    DOI 10.1016/j.ijrobp.2007.12.030, PubMed 18355976
18. Vistad I, Kristensen GB, Fosså SD, Dahl AA, Mørkrid L (2008)
    Intestinal malabsorption in long-term survivors of cervical cancer treated with radiotherapy
    Int J Radiat Oncol Biol Phys, 73 (4), 1141-7
    DOI 10.1016/j.ijrobp.2008.05.064, PubMed 18760883
19. Wang Z, Tropè CG, Suo Z, Trøen G, Yang G, Nesland JM, Holm R (2008)
    The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas
    BMC Cancer, 8, 308
    DOI 10.1186/1471-2407-8-308, PubMed 18950492

Publications 2007

1. Davidson B, Berner A, Trope' CG, Wang TL, Shih IeM (2007)
   Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions
   Hum Pathol, 38 (7), 1030-6
   DOI 10.1016/j.humpath.2006.12.009, PubMed 17391728
2. Davidson B, Skrede M, Silins I, Shih IeM, Trope CG, Flørenes VA (2007)
   Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma
   Cancer, 110 (6), 1264-71
   DOI 10.1002/cncr.22918, PubMed 17647260
3. Hoei-Hansen CE, Kraggerud SM, Abeler VM, Kaern J, Rajpert-De Meyts E, Lothe RA (2007)
   Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers
   Mol Cancer, 6, 12
   DOI 10.1186/1476-4598-6-12, PubMed 17274819
4. Holm R, Knopp S, Kumar R, Lee J, Nesland JM, Tropè C, Callen DF (2007)
   Expression of ZNF652, a novel zinc finger protein, in vulvar carcinomas and its relation to prognosis
   J Clin Pathol, 61 (1), 59-63
   DOI 10.1136/jcp.2006.045864, PubMed 17468294
5. Khouja MH, Baekelandt M, Nesland JM, Holm R (2007)
   The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma
   Int J Gynecol Pathol, 26 (4), 418-25
   DOI 10.1097/pgp.0b013e31804216a0, PubMed 17885492
6. Kleinberg L, Flørenes VA, Silins I, Haug K, Trope CG, Nesland JM, Davidson B (2007)
   Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma
   Cancer, 109 (2), 228-38
   DOI 10.1002/cncr.22426, PubMed 17167759
7. Liavaag AH, Dørum A, Bjøro T, Oksefjell H, Fosså SD, Tropé C, Dahl AA (2007)
   A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach
   Gynecol Oncol, 108 (2), 348-54
   DOI 10.1016/j.ygyno.2007.10.009, PubMed 17996925
8. Liavaag AH, Dørum A, Fosså SD, Tropé C, Dahl AA (2007)
   Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones?
   J Clin Oncol, 25 (15), 2049-56
   DOI 10.1200/JCO.2006.09.1769, PubMed 17513809
9. Lyng H, Sitter B, Bathen TF, Jensen LR, Sundfør K, Kristensen GB, Gribbestad IS (2007)
   Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas
   BMC Cancer, 7, 11
   DOI 10.1186/1471-2407-7-11, PubMed 17233882
10. Marth C, Walker JL, Barakat RR, Casado A, Gadducci A, Miller B, Odicino F, Pujade-Lauraine E, Sehouli J, Tropé C, Wenzel L, Zeimet AG (2007)
    Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer
    Cancer, 109 (4), 645-9
    DOI 10.1002/cncr.22467, PubMed 17238177
11. Oksefjell H, Sandstad B, Tropé C (2007)
    Improved survival for stage IIIC ovarian cancer patients treated at the Norwegian Radium Hospital between 1984 and 2001
    Eur J Gynaecol Oncol, 28 (4), 256-62
    PubMed 17713088
12. Paulsen T, Ree AH, Kaern J, Kjaerheim K, Bassarova A, Berner A, Haldorsen T, Tropé C, Nesland JM (2007)
    Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation
    Eur J Gynaecol Oncol, 28 (5), 356-63
    PubMed 17966213
13. Sert B, Abeler V (2007)
    Robotic radical hysterectomy in early-stage cervical carcinoma patients, comparing results with total laparoscopic radical hysterectomy cases. The future is now?
    Int J Med Robot, 3 (3), 224-8
    DOI 10.1002/rcs.152, PubMed 17924449
14. Trimble EL, Davis J, Disaia P, Fujiwara K, Gaffney D, Kristensen G, Ledermann J, Pfisterer J, Quinn M, Reed N, Schoenfeldt M, Thigpen JT, Gynecologic Cancer Intergroup (2007)
    Clinical trials in gynecological cancer
    Int J Gynecol Cancer, 17 (3), 547-56
    DOI 10.1111/j.1525-1438.2007.00667.x, PubMed 17504371
15. Tropé C, Kaern J (2007)
    Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature
    J Clin Oncol, 25 (20), 2909-20
    DOI 10.1200/JCO.2007.11.1013, PubMed 17617522
16. Vergote I, van der Zee AG, Kesic V, Sert B, Robova H, Rob L, Reed N, Luesley DM, Leblanc E, Hagen B, Gitsch G, du Bois A, di Vagno G, Colombo N, Beller U, Ayhan A, Jacobs I (2007)
    ESGO statement on cervical cancer vaccination
    Int J Gynecol Cancer, 17 (6), 1183-5
    DOI 10.1111/j.1525-1438.2007.01129.x, PubMed 17997794
17. Vistad I, Fosså SD, Kristensen GB, Dahl AA (2007)
    Chronic fatigue and its correlates in long-term survivors of cervical cancer treated with radiotherapy
    BJOG, 114 (9), 1150-8
    DOI 10.1111/j.1471-0528.2007.01445.x, PubMed 17655733
18. Vistad I, Fosså SD, Kristensen GB, Mykletun A, Dahl AA (2007)
    The sexual activity questionnaire: pychometric properties and normative data in a norwegian population sample
    J Womens Health (Larchmt), 16 (1), 139-48
    DOI 10.1089/jwh.2006.0052, PubMed 17324105
19. Wang Y, Kristensen GB, Børresen-Dale AL, Helland A (2007)
    TP53 mutations and codon 72 genotype--impact on survival among ovarian cancer patients
    Ann Oncol, 18 (5), 964-6
    DOI 10.1093/annonc/mdm134, PubMed 17488735
20. Wu Q, Lind GE, Aasheim HC, Micci F, Silins I, Tropé CG, Nesland JM, Lothe RA, Suo Z (2007)
    The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers
    Epigenetics, 2 (4), 237-43
    DOI 10.4161/epi.2.4.5406, PubMed 18281782
21. Wu Q, Lothe RA, Ahlquist T, Silins I, Tropé CG, Micci F, Nesland JM, Suo Z, Lind GE (2007)
    DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets
    Mol Cancer, 6, 45
    DOI 10.1186/1476-4598-6-45, PubMed 17623056
22. Zhang MZ, Qiao YH, Nesland JM, Trope C, Kennedy A, Chen WT, Suo ZH (2007)
    Expression of seprase in effusions from patients with epithelial ovarian carcinoma
    Chin Med J (Engl), 120 (8), 663-8
    PubMed 17517181

Publications 2006

1. [No authors] (2006)
   An international perspective on surgical health care and education
   J Am Coll Surg, 204 (1), 148-57
   DOI 10.1016/j.jamcollsurg.2006.09.021, PubMed 17189123
2. Aghmesheh M, Suo Z, Friedlander M, Nesland JM, Kaern J, Stewart M, Kconfab, Dorum A, Tucker KM, Buckley MF (2006)
   Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas
   Pathology, 38 (2), 145-51
   DOI 10.1080/00313020600561526, PubMed 16680901
3. Andersen A, Warren DJ, Brunsvig PF, Aamdal S, Kristensen GB, Olsen H (2006)
   High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection
   BMC Clin Pharmacol, 6, 2
   DOI 10.1186/1472-6904-6-2, PubMed 16412237
4. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Børresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van de Vijver MJ, Brown PO (2006)
   Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers
   PLoS Med, 3 (3), e47
   DOI 10.1371/journal.pmed.0030047, PubMed 16417408
5. Davidson B, Espina V, Steinberg SM, Flørenes VA, Liotta LA, Kristensen GB, Tropé CG, Berner A, Kohn EC (2006)
   Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling
   Clin Cancer Res, 12 (3 Pt 1), 791-9
   DOI 10.1158/1078-0432.CCR-05-2516, PubMed 16467090
6. Davidson B, Shafat I, Risberg B, Ilan N, Trope' CG, Vlodavsky I, Reich R (2006)
   Heparanase expression correlates with poor survival in metastatic ovarian carcinoma
   Gynecol Oncol, 104 (2), 311-9
   DOI 10.1016/j.ygyno.2006.08.045, PubMed 17030350
7. Davidson B, Trope' CG, Wang TL, Shih IeM (2006)
   Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival
   Gynecol Oncol, 103 (3), 814-9
   DOI 10.1016/j.ygyno.2006.05.042, PubMed 16844205
8. Dong HP, Elstrand MB, Holth A, Silins I, Berner A, Trope CG, Davidson B, Risberg B (2006)
   NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma
   Am J Clin Pathol, 125 (3), 451-8
   DOI 10.1309/15B66DQMFYYM78CJ, PubMed 16613351
9. Elloul S, Silins I, Tropé CG, Benshushan A, Davidson B, Reich R (2006)
   Expression of E-cadherin transcriptional regulators in ovarian carcinoma
   Virchows Arch, 449 (5), 520-8
   DOI 10.1007/s00428-006-0274-6, PubMed 17024425
10. Gorovetz M, Baekelandt M, Berner A, Trope' CG, Davidson B, Reich R (2006)
    The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma
    Gynecol Oncol, 103 (3), 831-40
    DOI 10.1016/j.ygyno.2006.06.042, PubMed 16919315
11. Holm R, Knopp S, Suo Z, Tropè C, Nesland JM (2006)
    Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis
    J Clin Pathol, 60 (10), 1086-91
    DOI 10.1136/jcp.2006.041194, PubMed 17158642
12. Knopp S, Holm R, Bjørge T, Tropé C, Nesland JM (2006)
    Cell cycle regulation in primary vulvar carcinomas and related lymph node metastases
    Histopathology, 49 (3), 311-2
    DOI 10.1111/j.1365-2559.2006.02457.x, PubMed 16918980
13. Knopp S, Nesland JM, Tropé C, Holm R (2006)
    p14ARF, a prognostic predictor in HPV-negative vulvar carcinoma
    Am J Clin Pathol, 126 (2), 266-76
    DOI 10.1309/e9e8y9wg5qe3lk29, PubMed 16891203
14. Knudsen A, Monstad SE, Dørum A, Lønning PE, Salvesen HB, Drivsholm L, Aarseth JH, Vedeler CA (2006)
    Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique
    Cancer Immunol Immunother, 55 (10), 1280-4
    DOI 10.1007/s00262-006-0121-2, PubMed 16429314
15. Kraus I, Molden T, Holm R, Lie AK, Karlsen F, Kristensen GB, Skomedal H (2006)
    Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas
    J Clin Microbiol, 44 (4), 1310-7
    DOI 10.1128/JCM.44.4.1310-1317.2006, PubMed 16597856
16. Lyng H, Brøvig RS, Svendsrud DH, Holm R, Kaalhus O, Knutstad K, Oksefjell H, Sundfør K, Kristensen GB, Stokke T (2006)
    Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer
    BMC Genomics, 7, 268
    DOI 10.1186/1471-2164-7-268, PubMed 17054779
17. Monstad SE, Storstein A, Dørum A, Knudsen A, Lønning PE, Salvesen HB, Aarseth JH, Vedeler CA (2006)
    Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique
    Clin Exp Immunol, 144 (1), 53-8
    DOI 10.1111/j.1365-2249.2006.03031.x, PubMed 16542365
18. Oksefjell H, Sandstad B, Trope C (2006)
    Ovarian cancer stage IIIC. Consequences of treatment level on overall and progression-free survival
    Eur J Gynaecol Oncol, 27 (3), 209-14
    PubMed 16800244
19. Paulsen T, Kaern J, Kjaerheim K, Haldorsen T, Tropé C (2006)
    Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer
    Gynecol Oncol, 102 (3), 447-52
    DOI 10.1016/j.ygyno.2006.01.035, PubMed 16516277
20. Paulsen T, Kjaerheim K, Kaern J, Tretli S, Tropé C (2006)
    Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals
    Int J Gynecol Cancer, 16 Suppl 1, 11-7
    DOI 10.1111/j.1525-1438.2006.00319.x, PubMed 16515561
21. Pradhan M, Abeler VM, Danielsen HE, Tropé CG, Risberg BA (2006)
    Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas
    Mod Pathol, 19 (9), 1227-35
    DOI 10.1038/modpathol.3800641, PubMed 16729014
22. Sert B, Abeler VM, Dørum A, Trope CG (2006)
    A new approach to treatment of early-stage cervical carcinoma: entire laparoscopic abdominal radical hysterectomy with bilateral pelvic lymphadenectomy without vaginal cuff closure--case reports
    Eur J Gynaecol Oncol, 27 (5), 513-8
    PubMed 17139990
23. Tropé C, Kaern J (2006)
    Primary surgery for ovarian cancer
    Eur J Surg Oncol, 32 (8), 844-52
    DOI 10.1016/j.ejso.2006.03.036, PubMed 16677797
24. Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MMO, Olivier M, Skomedal H, Hainaut P, Trope CG, Abeler VM, Nesland JM, Borresen-Dale AL, Helland A (2006)
    Effect of the codon 72 polymorphism (c.215G > C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma (vol 24, pg 21, 2004)
    Hum. Mutat., 27 (2), 209-210
25. Wu Q, Suo Z, Kristensen GB, Baekelandt M, Nesland JM (2006)
    The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma
    Gynecol Oncol, 102 (1), 15-21
    DOI 10.1016/j.ygyno.2005.11.034, PubMed 16499955